Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
EFPIA Japan said on March 31 that Takahiko Iwaya, Japan president of Sanofi, has been reappointed as the chair of the organization, effective March 27, for a new two-year term until March 2027. “Japan’s pharmaceutical industry is in a period…
To read the full story
Related Article
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- EFPIA Japan Appoints Sanofi’s Takahiko Iwaya as New Chair
August 25, 2021
ORGANIZATION
- Japan Falling Behind US, China in Pharma Innovation, EFPIA Chief Urges Action
October 15, 2026
- US VC Coalition Urges Japan to Rethink Drug Pricing, Labor Rules
October 13, 2026
- PhRMA Sues CMS over Medicare MFN Model, Calls It Unlawful Overreach
October 9, 2026
- Japan Generic Group Calls for Clearer Patent Extension Rules
October 9, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…